Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

Can large national health plans make an impact in reducing prescribing of high-risk medications to people with Alzheimer's ...

The global neuromodulation device market will be worth $11.4bn by 2033, as per a market model from GlobalData.

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

Alzheimer’s disease robs patients of so much more than their health. It can rewire their personalities and undermine a ...

Cannabis is emerging as a tool in dementia care, offering relief from anxiety and agitation when traditional medications fall ...

In the last two years, two drugs have been federally approved to slow the onset of Alzheimer's disease in its early stages, ...

Raquel Sánchez Valle, coordinator of the Behavior and Dementia Group of the Spanish Society ... Given the complexity of ...

As people age, the body changes as part of the normal ageing process, such as greying hair and loss of elasticity in the skin ...

Dementia is a condition that affects memory, thinking, and the ability to perform everyday tasks. As it progresses, it can ...

Obstructive sleep apnea has been linked to an increased risk of dementia in a new study—and the association was particularly ...

Many, including Alzheimer's disease, are treatable. Others, such as depression, thyroid problems, severe nutritional deficiency, or medication interaction, may be reversible. Patients who are ...